

Table 2: Schedules, doses and administration for viral vector-based vaccines

Product	AstraZeneca / COVISHIELD	Janssen
Authorized ages for use	18 years of age and older * [£]	18 years of age and older [£]
Dose	0.5 mL (5 x 10 ¹⁰ viral particles)	0.5 mL (5 x 10 ¹⁰ viral particles)
Schedule	2 doses, 8 to 12 weeks apart **	1 dose
Route of administration	IM	IM
Primary storage requirements	+2°C to +8°C	+2°C to +8°C
Usage limit post puncture	6 hours at room temperature (up to +30°C) Or 48 hours at +2°C to +8°C	3 hours at room temperature (up to +25°C) Or 6 hours at +2°C to +8°C

* These vaccines are no longer being offered as a first dose, unless there is a contraindication to the mRNA vaccines, or as advised by the Medical Health Officer or an allergist.

[£] Informed consent should include the risk and symptoms of Thrombosis with Thrombocytopenia Syndrome (TTS) versus the individual's risk of serious illness from COVID-19, as well as the need to seek immediate medical care should symptoms develop.

** While the approved minimum interval between dose 1 and 2 is 4 weeks, the preferred interval is 8 to 12 weeks. If the administration of the second dose is delayed, the series does not need to be restarted. As of September 13, 2021, a 3-dose primary series is recommended for moderately to severely immunocompromised individuals in B.C. as outlined on the [government of B.C. website](#). Moderna COVID-19 vaccine is preferentially recommended for all doses in the series. For moderately to severely immunocompromised individuals who completed a 1-dose primary series with the Janssen COVID-19 vaccine, an additional dose of Moderna COVID-19 vaccine is recommended.